Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 42 yuan [2][9]. Core Views - The company reported a revenue of 443 million yuan for 2024, a decrease of 5.90% year-on-year, and a net profit attributable to shareholders of 135 million yuan, down 7.11% [2][4]. - In Q4 2024, the company experienced a revenue increase of 31.59% to 124 million yuan and a net profit increase of 37.92% to 38 million yuan, indicating a potential upward turning point in performance [2][4]. - The company plans to distribute a cash dividend of 0.6 yuan per share (before tax) to all shareholders [2]. Financial Summary - Total revenue is projected to grow from 443 million yuan in 2024 to 828 million yuan by 2027, with a compound annual growth rate (CAGR) of 21.3% [4]. - Net profit is expected to increase from 136 million yuan in 2024 to 281 million yuan in 2027, reflecting a CAGR of 23.1% [4]. - Earnings per share (EPS) are forecasted to rise from 1.12 yuan in 2024 to 2.34 yuan in 2027, with corresponding price-to-earnings (P/E) ratios decreasing from 31 to 15 [4][9]. Business Performance - The company's medical endoscope business generated 345 million yuan in revenue for 2024, a decline of 7.04%, while optical revenue was 95 million yuan, down 1.80% [9]. - The company has seen a recovery in revenue growth in Q4 2024 and Q1 2025, attributed to reduced inventory levels among overseas clients and increasing demand [9]. - The company has completed certifications for its overseas subsidiaries, which mitigates trade friction risks and allows for smoother order fulfillment in the U.S. market [9]. Product Development - The company has launched a full range of laparoscopic products in the domestic market and has developed new endoscope products for various medical fields, which are now registered and available for sale [9]. - New products for the U.S. market, including a 4mm hysteroscope, have entered mass production, with further collaborations on next-generation systems with U.S. clients [9].

Core Viewpoint - The company reported a decline in revenue and net profit for 2024, but showed signs of recovery in Q4 2024 and Q1 2025, with a positive outlook for future earnings growth driven by inventory reduction among overseas clients and new product launches [1][2][4]. Financial Performance - For the full year 2024, the company achieved revenue of 443 million yuan (down 5.90%) and a net profit attributable to shareholders of 135 million yuan (down 7.11%) [1] - In Q4 2024, revenue was 124 million yuan (up 31.59%) and net profit attributable to shareholders was 38 million yuan (up 37.92%) [1] - For Q1 2025, revenue reached 147 million yuan (up 24.86%) and net profit attributable to shareholders was 47 million yuan (up 21.45%) [1] Product and Market Development - The company’s medical endoscope business generated revenue of 345 million yuan in 2024 (down 7.04%), while optical revenue was 95 million yuan (down 1.80%) [2] - International revenue for 2024 was 306 million yuan (down 6.5%), and domestic revenue was 135 million yuan (down 4.70%) [2] - The company has successfully launched a full range of laparoscopes and various endoscope products in the domestic market, and new products for the U.S. market are set to enter mass production [3] Future Outlook - The company expects net profits attributable to shareholders for 2025-2027 to be 180 million, 230 million, and 280 million yuan, representing year-on-year growth of 34.8%, 25.4%, and 23.1% respectively [4] - The estimated EPS for the same period is projected to be 1.51, 1.90, and 2.34 yuan, with corresponding PE ratios of 23, 19, and 15 times [4] - A target price of approximately 42 yuan is set for 2025, based on a valuation of 28 times [4]

公司研究 证 券 研 究 报 告 海泰新光（688677）2024 年报及 2025 年一季报点评 推荐（维持） 业绩拐点向上，海外子公司完成认证 目标价：42 元 事项： ❖ 公司发布 24 年年报及 25 年一季报，24 年全年营收 4.43 亿元（-5.90%），归母 净利润 1.35 亿元（-7.11%），扣非归母净利润 1.29 亿元（-5.26%）。24Q4，营 收 1.24 亿元（+31.59%），归母净利润 0.38 亿元（+37.92%），扣非归母净利润 0.40 亿元（+57.44%）。25Q1，营收 1.47 亿元（+24.86%），归母净利润 0.47 亿 元（+21.45%），扣非归母净利润 0.46 亿元（+26.89%）。公司拟向全体股东每 股派发现金红利 0.6 元（含税）。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 443 | 558 | 682 | 828 | | 同比增速(%) | - ...

调研纪要：投资者主要就2024年年报及2025年一季报主要财务指标、品牌矩阵、产品结构、产品毛利 率、终端销售情况等问题进行了交流，可参阅前次活动记录表之问和已披露公告。接待过程中，公司严 格按照《信息披露管理制度》等规定，保证信息披露的真实、准确、完整、及时、公平，没有出现未公 开重大信息泄露等情况。 机构简介： 弘尚资产由来自公募基金的优秀团队和全球风险投资巨擘红杉资本联合创建，公司成立于2013年10月， 是红杉资本在中国唯一的权益证券资产管理平台。公司成立以来，凭借优秀业绩和稳健运作，屡获金阳 光、金长江及金牛奖等行业大奖，跻身国内知名阳光私募基金公司。弘尚资产专注于绝对收益目标的权 益类投资策略，以基本面研究驱动的权益类资产管理能力为核心竞争力，公司投研团队包括大型基金公 司高管、外资投研主管、金牛基金经理、新财富最佳分析师等资深投研大将。非投研板块的业务带头人 全部来自公募基金，具有深厚的管理经验和行业影响力，确保公司持续稳健发展。公司是中国基金业协 会会员，具备投顾资格。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688677 证券简称：海泰新光 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 1 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 目录 | 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议须知 | | 1 | | --- | --- | --- | | 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议议程 | | 3 | | 议案一 《青岛海泰新光科技股份有限公司 2024 年年度报告全文及其摘要》 | | 5 | | 议案二 《青岛海泰新光科技股份有限公司 2024 年度董事会工作报告》 | | 6 | | 议案三 《青岛海泰新光科技股份有限公司 2024 年度监事会工作报告》 | | 7 | | 议案四 《青岛海泰新光科技股份有限公司 2024 年度财务决算报告》 | | 8 | | 议案五 《青岛海泰新光科技股份有限公司 2024 年度利润分配方案》 | | 9 | | 议案六 2025 年度独立董事津贴的议案》 | 《关于 | 10 | | 议案七 2 ...

青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 证券代码：688677 证券简称：海泰新光 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 目录 | 青岛海泰新光科技股份有限公司 | 2024 | 年年度股东大会会议须知 1 | | --- | --- | --- | | 青岛海泰新光科技股份有限公司 | 2024 | 年年度股东大会会议议程 3 | | | | 1 | 青岛海泰新光科技股份有限公司 2024 年年度股东大会会议资料 上述登记材料均需提供复印件一份，个人登记材料复印件须个人签字，法定 代表人证明文件复印件须加盖公司公章，经验证后领取会议资料，方可出席会议。 会议开始后，由会议主持人宣布现场出席会议的股东人数及其所持有表决权的股 份总数，在此之后进场的股东无权参与现场投票表决。 三、会议按照会议通知上所列顺序审议、表决议案。 | 议案一 《青岛海泰新光科技股份有限公司 | | 2024 | 年年度报告全文及其摘要》 | 5 | | --- | --- | --- | --- | --- | | 议案二 《青岛海泰新光科技股份有限公司 | | ...

股票研究 /[Table_Date] 2025.05.03 2025-05-07 业绩持续复苏，Q1 发货量大幅增长 海泰新光 2024A & 2025Q1 业绩点评 本报告导读： 24 年前三季度下游客户去库影响发货节奏，24Q3 以来发货逐步恢复，25Q1 发货 量同比增长 40%以上，维持增持评级。 投资要点： | [Table_Finance] 财务摘要（百万元） | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入 | 471 | 443 | 556 | 681 | 826 | | (+/-)% | -1.3% | -5.9% | 25.5% | 22.6% | 21.2% | | 净利润（归母） | 146 | 135 | 179 | 223 | 275 | | (+/-)% | -20.2% | -7.1% | 31.9% | 24.8% | 23.5% | | 每股净收益（元） | 1.21 | 1.12 | 1.48 | 1.85 | 2.28 | | 净资产收益率(%) ...

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 46.69, corresponding to a 2025 PE of 32X [4][8]. Core Insights - The company experienced a revenue of RMB 443 million in 2024, a decrease of 5.90% year-on-year, while the net profit attributable to shareholders was RMB 135 million, down 7.11% [4][8]. - In Q1 2025, the company reported a revenue of RMB 147 million, reflecting a significant increase of 24.86% year-on-year, and a net profit of RMB 47 million, up 21.45% [4][8]. - The company’s EPS forecasts for 2025-2026 are RMB 1.48 and RMB 1.85, with a new forecast for 2027 at RMB 2.28 [4][8]. Financial Summary - The financial summary indicates that in 2023, the company had a revenue of RMB 471 million, which decreased to RMB 443 million in 2024, with projections of RMB 556 million in 2025 and RMB 681 million in 2026 [3][4]. - The net profit attributable to shareholders was RMB 146 million in 2023, decreasing to RMB 135 million in 2024, with an expected increase to RMB 179 million in 2025 and RMB 223 million in 2026 [3][4]. - The gross profit margin for 2024 was 64.51%, showing a slight increase from the previous year, and the first quarter of 2025 reported a gross profit margin of 64.98% [11]. Customer Orders and Market Expansion - Customer orders are recovering, with shipment volumes increasing significantly, particularly in Q1 2025, where shipments grew over 40% year-on-year and quarter-on-quarter [9]. - The company’s ODM business revenue was RMB 281 million in 2024, accounting for 63.81% of total revenue, while the self-owned brand product revenue was RMB 65.22 million, representing 14.80% [10]. Profitability and Cost Management - The overall gross profit margin remained stable, with expectations for long-term profitability to be maintained due to improvements in overseas subsidiaries' capacity and management [11]. - The company has increased its R&D and marketing expenses significantly in 2024 compared to 2023, which is expected to support future growth [11].

证券代码：688677 证券简称：海泰新光 公告编号：2025-028 公司于 2025 年 3 月 3 日召开第四届董事会第三次会议，审议通过了《关于以 集中竞价交易方式回购公司股份方案的议案》（以下简称"本次回购方案"），同意 公司以自有资金及回购专项贷款资金通过上海证券交易所交易系统以集中竞价交 易方式回购公司已发行的部分人民币普通股股票。回购的股份将在未来适宜时机 全部用于员工持股计划或股权激励，回购价格不超过 59 元/股（含），回购资金总 额不低于人民币 5,000 万元（含），不超过人民币 10,000 万元（含），回购期限自 公司董事会审议通过本次回购方案之日起 12 个月内。具体内容详见公司于 2025 年 3 月 5 日在上海证券交易所网站（www.sse.com.cn）上披露的《青岛海泰新光 科技股份有限公司关于以集中竞价交易方式回购股份的预案》（公告编号： 2025-006）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应当在每个月的前 3 个交易日 内公告截至上月末的回购进展情况，现将公 ...

特此公告。 青岛海泰新光科技股份有限公司董事会 青岛海泰新光科技股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，青岛海泰新光科技股份有限公司（以下 简称"公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网 络有限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）或关注微信公众号（名称：全景财经）或下载全景路演 APP,参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司高管将以在线交流形式就公司治理、发展战略、经营状况等投资者关注 的问题与投资者进行沟通与交流，欢迎广大投资者踊跃参与。 证券代码：688677 证券简称：海泰新光 公告编号：2025-027 2025 年 5 月 7 日 1 ...